NCT01311986

Brief Summary

The aim of this study is to measure the serum levels of CCL17, CCL18, CCL22 and CXCL10 and their expression levels in epidermis in AD and ND patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2010

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2010

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 8, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 10, 2011

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2011

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2012

Completed
Last Updated

April 22, 2011

Status Verified

March 1, 2011

Enrollment Period

11 months

First QC Date

March 8, 2011

Last Update Submit

April 21, 2011

Conditions

Atopic DermatitisNummular Eczema

Keywords

atopic dermatitisnummular eczemachemokines

Study Arms (3)

Patients with atopic dermatitis

Patients with nummular eczema

Normal control

Eligibility Criteria

Age20 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

patients with atopic dermatitis patients with nummular eczema without atopy

You may qualify if:

  • age:20\~40, atopic dermatitis, BSA\>10%, no asthma
  • age:20\~40, nummular patches\>10, no atopy

You may not qualify if:

  • systemic immunosuppresive agents within 4 weeks
  • high dose topical immunosuppresive agents within 4 weeks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital

Taipei, Taipei, 100, Taiwan

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Patient serum, and epidermal keratinocytes for mRNA retrieval

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, EczematousHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Hsien-Ching Chiu, MD

    Department of Dermatology, National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 8, 2011

First Posted

March 10, 2011

Study Start

November 1, 2010

Primary Completion

October 1, 2011

Study Completion

March 1, 2012

Last Updated

April 22, 2011

Record last verified: 2011-03

Locations

TW(1)